Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Radiation for Cisplatin-Ineligible SCCHN
NCT02609503Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2016
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started May 2016; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02609503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609503.